MediWound posts investor presentation on enzymatic burn and chronic-wound therapies NexoBrid, EscharEx
Reuters2026/08/13 11:06- MediWound outlined a growth plan centered on NexoBrid, marketed for severe burn eschar removal, with 2025 revenue of USD 17 million.
- EscharEx, an investigational chronic-wound debridement therapy, targets a USD 4 billion U.S. market; VLU program in Phase 3.
- Company highlighted a cash balance of USD 36 million with no debt; cited runway through profitability.
- Presentation flagged potential additional proceeds of up to USD 29 million from Series A warrant exercises expiring in November 2026.
- New cGMP sterile manufacturing facility designed to expand capacity sixfold; regulatory approvals expected in 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Community Reacts As Pundit Claims XRP Will Be Priced At $2,953 By Q2 2027
Colgate-Palmolive (CL.US) plans to sell part of its personal care brands, with a total transaction amount possibly exceeding 1.1 billions USD.
According to sources familiar with the matter, Colgate is exploring the sale of some of its mass-market personal care brands. The company currently plans to divest only a few brands within its personal care business, and the combined sale price may exceed 1 billion dollars.
EdiliziAcrobatica announces shareholder meeting notice
Crypto prices
More
